Key clinical point: High-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who meet trial eligibility but require urgent treatment are being widely excluded from clinical trials.
Major finding: The clinical trial accrual rate was 18%. Of 207 patients who were not enrolled, 43 were excluded because of a perceived need for urgent treatment due to symptoms or rapid progression.
Study details: A retrospective analysis of 251 patients with newly diagnosed DLBCL.
Disclosures: No funding sources were reported. The authors reported financial relationships with Genentech, Bayer, Ascerta, Curis, and Kite Gilead.
Loh KP et al. Leuk Lymphoma. 2019 Jul 8. doi: 10.1080/10428194.2019.1639172